Early-onset drug-induced parkinsonism after exposure to offenders implies nigrostriatal dopaminergic dysfunction

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 89, Issue 2, 2018, Pages 169-174

  Chung, Seok Jong ^a   Yoo, Han Soo ^a   Moon, Hyojeong ^b   Oh, Jungsu S ^b   Kim, Jae Seung ^b   Park, Yong Hee ^c   Hong, Jin Yong ^c   Ye, Byoung Seok ^a   Sohn, Young H ^a   Lee, Phil Hyu ^a  

^a Yonsei University College of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Yonsei University Wonju   (South Korea)

Author keywords

dopamine transporter; drug induced parkinsonism; Parkinson's disease

Indexed keywords

DOPAMINE TRANSPORTER; 2-CARBOMETHOXY-8-(3-FLUOROPROPYL)-3-(4-IODOPHENYL)TROPANE; ANTICONVULSIVE AGENT; ANTIEMETIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; FLUORINE; NEUROLEPTIC AGENT; RADIOPHARMACEUTICAL AGENT; SEROTONIN UPTAKE INHIBITOR; TROPANE DERIVATIVE; VALPROIC ACID;

AGED; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; DRUG EXPOSURE; DRUG INDUCED PARKINSONISM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NIGRONEOSTRIATAL SYSTEM; ODOR RECOGNITION TEST; OFFENDER; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PUTAMEN; VENTRAL STRIATUM; CASE CONTROL STUDY; CHEMICALLY INDUCED; CONVALESCENCE; CORPUS STRIATUM; DEPRESCRIPTION; DIAGNOSTIC IMAGING; METABOLISM; MIDDLE AGED; NEOSTRIATUM; PATHOPHYSIOLOGY; TIME FACTOR;

AGED; ANTICONVULSANTS; ANTIEMETICS; ANTIPSYCHOTIC AGENTS; CALCIUM CHANNEL BLOCKERS; CASE-CONTROL STUDIES; CAUDATE NUCLEUS; CORPUS STRIATUM; DEPRESCRIPTIONS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; MALE; MIDDLE AGED; NEOSTRIATUM; PARKINSONIAN DISORDERS; POSITRON-EMISSION TOMOGRAPHY; PUTAMEN; RADIOPHARMACEUTICALS; RECOVERY OF FUNCTION; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS; TROPANES; VALPROIC ACID; VENTRAL STRIATUM;

EID: 85044587708     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2017-315873     Document Type: Article

References (40)

1. Shin HW, Chung SJ. Drug-induced parkinsonism. J Clin Neurol 2012;8:15-21.
2. Erro R, Bhatia K P, Tinazzi M. parkinsonism following neuroleptic exposure: a double-hit hypothesis? Mov Disord 2015;30:780-5.
3. Tolosa E, Coelho M, Gallardo M. DaT imaging in drug-induced and psychogenic parkinsonism. Mov Disord 2003;18(suppl 7):s28-33.
4. Hong J Y, Sunwoo MK, Oh JS, et al. Persistent Drug-Induced parkinsonism in patients with Normal Dopamine Transporter Imaging. PLoS One 2016;11:e0157410.
5. Lorberboym M, Treves TA, Melamed E, et al. [123I]-Fp/cIT specT imaging for distinguishing drug-induced parkinsonism from parkinson's disease. Mov Disord 2006;21:510-4.
6. Tinazzi M, Morgante F, Matinella A, et al. Imaging of the dopamine transporter predicts pattern of disease progression and response to levodopa in patients with schizophrenia and parkinsonism: a 2-year follow-up multicenter study. Schizophr Res 2014;152:344-9.
7. Marsden CD, Jenner P. The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychol Med 1980;10:55-72.
8. Farde L, Wiesel FA, Halldin C, et al. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 1988;45:71-6.
9. Bondon-Guitton E, Perez-Lloret S, Bagheri H, et al. Drug-induced parkinsonism: a review of 17 years' experience in a regional pharmacovigilance center in France. Mov Disord 2011;26:2226-31.
10. Jiménez-Jiménez FJ, Ortí-pareja M, Ayuso-peralta L, et al. Drug-induced parkinsonism in a movement disorders unit: a four-year survey. Parkinsonism Relat Disord 1996;2:145-9.
11. Manolio TA, Kronmal RA, Burke GL, et al. Magnetic resonance abnormalities and cardiovascular disease in older adults. The cardiovascular health study. Stroke 1994;25:318-27.
12. Ham JH, Lee JJ, Kim JS, et al. Is Dominant-side Onset associated With a Better Motor compensation in parkinson's Disease? Mov Disord 2015;30:1921-5.
13. Mawlawi O, Martinez D, Slifstein M, et al. Imaging human mesolimbic dopamine transmission with positron emission tomography: I. accuracy and precision of D(2) receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab 2001;21:1034-57.
14. Oh JS, Oh M, Chung SJ, et al. Cerebellum-specifc 18F-FDG peT analysis for the detection of subregional glucose metabolism changes in spinocerebellar ataxia. Neuroreport 2014;25:1198-202.
15. Tinazzi M, Ottaviani S, Isaias IU, et al. [123I]Fp-cIT speT imaging in drug-induced parkinsonism. Mov Disord 2008;23:1825-9.
16. Wang J, Zuo CT, Jiang Y P, et al. 18F-Fp-cIT peT imaging and spM analysis of dopamine transporters in parkinson's disease in various hoehn & Yahr stages. J Neurol 2007;254:185-90.
17. Ossowska K. Neuronal basis of neuroleptic-induced extrapyramidal side effects. Pol J Pharmacol 2002;54:299-312.
18. Gunne LM, Andrén PE. An animal model for coexisting tardive dyskinesia and tardive parkinsonism: a glutamate hypothesis for tardive dyskinesia. Clin Neuropharmacol 1993;16:90-5.
19. Cannella M, Motolese M, Bucci D, et al. Changes in the expression of genes encoding for mGlu4 and mGlu5 receptors and other regulators of the indirect pathway in acute mouse models of drug-induced parkinsonism. Neuropharmacology 2015;95:50-8.
20. Kulisevsky J, Poyurovsky M. adenosine a2a-receptor antagonism and pathophysiology of parkinson's disease and drug-induced movement disorders. Eur Neurol 2012;67:4-11.
21. Crisafulli C, Drago A, Sidoti A, et al. A genetic dissection of antipsychotic induced movement disorders. Curr Med Chem 2013;20:312-30.
22. Meredith GE, Switzer RC, Napier TC. short-term, D2 receptor blockade induces synaptic degeneration, reduces levels of tyrosine hydroxylase and brain-derived neurotrophic factor, and enhances D2-mediated fring in the ventral pallidum. Brain Res 2004;995:14-22.
23. Fa M, Mereu G, Ghiglieri V, et al. Electrophysiological and pharmacological characteristics of nigral dopaminergic neurons in the conscious, head-restrained rat. Synapse 2003;48:1-9.
24. Burkhardt C, Kelly J P, Lim YH, et al. Neuroleptic medications inhibit complex I of the electron transport chain. Ann Neurol 1993;33:512-7.
25. Veitch K, Hue L. Flunarizine and cinnarizine inhibit mitochondrial complexes I and II: possible implication for parkinsonism. Mol Pharmacol 1994;45:158-63.
26. Shuaib UA, Rajput AH, Robinson CA, et al. Neuroleptic-induced parkinsonism: clinicopathological study. Mov Disord 2016;31:360-5.
27. Booij J, Kemp P. Dopamine transporter imaging with [(123)I]Fp-cIT specT: potential effects of drugs. Eur J Nucl Med Mol Imaging 2008;35:424-38.
28. Lavalaye J, Linszen DH, Booij J, et al. Dopamine transporter density in young patients with schizophrenia assessed with [123]Fp-cIT specT. Schizophr Res 2001;47:59-67.
29. Shin HW, Kim JS, Oh M, et al. Clinical features of drug-induced parkinsonism based on [18F] Fp-cIT positron emission tomography. Neurol Sci 2015;36:269-74.
30. McGeer PL, McGeer EG, Hattori T. Dopamine-acetylcholine-GaBa neuronal linkages in the extrapyramidal and limbic systems. Adv Biochem Psychopharmacol 1977;16:397-402.
31. Cilia R, Marotta G, Belletti A, et al. Reversible dopamine transporter reduction in drug-induced parkinsonism. Mov Disord 2014;29:575-7.
32. Susatia F, Fernandez HH. Drug-induced parkinsonism. Curr Treat Options Neurol 2009;11:162-9.
33. Hardie RJ, Lees AJ. Neuroleptic-induced parkinson's syndrome: clinical features and results of treatment with levodopa. J Neurol Neurosurg Psychiatry 1988;51:850-4.
34. Kim JS, Oh YS, Kim YI, et al. Combined use of βI-metaiodobenzylguanidine (MIBG) scintigraphy and dopamine transporter (DaT) positron emission tomography (peT) predicts prognosis in drug-induced parkinsonism (DIp): a 2-year follow-up study. Arch Gerontol Geriatr 2013;56:124-8.
35. Eisensehr I, Linke R, Tatsch K, et al. Increased muscle activity during rapid eye movement sleep correlates with decrease of striatal presynaptic dopamine transporters. IpT and IBZM specT imaging in subclinical and clinically manifest idiopathic ReM sleep behavior disorder, parkinson's disease, and controls. Sleep 2003;26:507-12.
36. Iranzo A, Valldeoriola F, Lomeña F, et al. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol 2011;10:797-805.
37. Takada M, Kono T, Kitai S T. Flunarizine induces a transient loss of tyrosine hydroxylase immunoreactivity in nigrostriatal neurons. Brain Res 1992;590:311-5.
38. Gill HS, DeVane CL, Risch SC. Extrapyramidal symptoms associated with cyclic antidepressant treatment: a review of the literature and consolidating hypotheses. J Clin Psychopharmacol 1997;17:377-89.
39. Brugger F, Bhatia K P, Besag FM. Valproate-associated parkinsonism: a critical review of the literature. CNS Drugs 2016;30:527-40.
40. Mateos JJ, Lomeña F, Parellada E, et al. Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait. Psychopharmacology 2007;191:805-11.